LX, L., A, S., G, K., L, M., R, W., AY, A., . . . MJ, S. (2026). Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials. JNCI cancer spectrum, 10(2), . https://doi.org/10.1093/jncics/pkaf127
Chicago Style (17th ed.) CitationLX, Li, et al. "Heterogeneous Treatment Effect of Immune Checkpoint Inhibitors by Pretreatment Prognosis in Randomized Controlled Trials." JNCI Cancer Spectrum 10, no. 2 (2026). https://doi.org/10.1093/jncics/pkaf127.
MLA (9th ed.) CitationLX, Li, et al. "Heterogeneous Treatment Effect of Immune Checkpoint Inhibitors by Pretreatment Prognosis in Randomized Controlled Trials." JNCI Cancer Spectrum, vol. 10, no. 2, 2026, https://doi.org/10.1093/jncics/pkaf127.
Warning: These citations may not always be 100% accurate.
